Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Monica Maccagno"'
Autor:
Monica Maccagno, Marta Tapparo, Gabriele Saccu, Letizia Rumiano, Sharad Kholia, Lorenzo Silengo, Maria Beatriz Herrera Sanchez
Publikováno v:
Medical Sciences, Vol 12, Iss 3, p 43 (2024)
The rise in biological therapies has revolutionized oncology, with immunotherapy leading the charge through breakthroughs such as CAR-T cell therapy for melanoma and B-ALL. Modified bispecific antibodies and CAR-T cells are being developed to enhance
Externí odkaz:
https://doaj.org/article/96f2969096fe4a7292b595a782e2b778
Autor:
Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Maria Labrador, Monica Maccagno, Michela Cumerlato, Federico Oreglia, Lorenzo Prever, Veronica Manicardi, Elisa Taiana, Domenica Ronchetti, Mattia D’Agostino, Francesca Gay, Alessandra Larocca, Lenka Besse, Giorgio Roberto Merlo, Emilio Hirsch, Alessia Ciarrocchi, Giorgio Inghirami, Antonino Neri, Roberto Piva
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-17 (2023)
Abstract Background Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomi
Externí odkaz:
https://doaj.org/article/d501676facca4dc6a35067bb270cd0fa
Autor:
Marta Tapparo, Gabriele Saccu, Chiara Pasquino, Valentina Fonsato, Claudio Medana, Valentina Schiavo, Enrica Mecarelli, Monica Maccagno, Lorenzo Silengo, Stefania Bruno, Giovanni Camussi, Maria Beatriz Herrera Sanchez
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Introduction: The lack of functional hepatocytes poses a significant challenge for drug safety testing and therapeutic applications due to the inability of mature hepatocytes to expand and their tendency to lose functionality in vitro. Previous studi
Externí odkaz:
https://doaj.org/article/2297f9d0135249cba1b41372e9ebb979
Autor:
Elisabetta Mereu, Damiano Abbo, Tina Paradzik, Michela Cumerlato, Cecilia Bandini, Maria Labrador, Monica Maccagno, Domenica Ronchetti, Veronica Manicardi, Antonino Neri, Roberto Piva
Publikováno v:
Cancers
Cancers; Volume 15; Issue 8; Pages: 2199
Cancers; Volume 15; Issue 8; Pages: 2199
Proteasome inhibitors (PIs) are extensively used for the therapy of multiple myeloma. However, patients continuously relapse or are intrinsically resistant to this class of drugs. In addition, adverse toxic effects such as peripheral neuropathy and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ddf6bae3e4ed7416ea4ac512e449dc3
http://fulir.irb.hr/8067/1/MereuE_Euchromatic_Cancers-15_2023_02199-v2.pdf
http://fulir.irb.hr/8067/1/MereuE_Euchromatic_Cancers-15_2023_02199-v2.pdf
